Skip to main content
S&P 5007,616.14+0.40%DOW52,129.73+0.07%NASDAQ26,172.50+0.73%BTC$75,699.00-0.86%ETH$2,388.96-1.10%GOLD$4,394.00+1.41%OIL$102.01-3.61%
Smart Investors Daily
NR

NASDAQ · NRXP

NRx Pharmaceuticals, Inc.

Healthcare · Biotechnology

$3.40

Down-$0.02 (-0.59%)

Updated Sep 16, 2026, 3:14 PM

SID Score

5.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
37.94M
P/E ratio
-1.28
Dividend yield
0.00%
52-week range
$1.62 – $5.06
Volume
1.26M
Avg. volume
441.62K

Price performance

NRXP price history

1M range · 20 trading sessions · Daily adjusted prices

NRXP closed at $3.40 after 20 trading sessions, down 1.16% for the selected period.

Last close
$3.40
Period change
-1.16%
Period low
$3.33
Period high
$3.67
Daily close
View OHLC price history
NRXP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$3.46$3.47$3.16$3.401.26M
Sep 14, 2026$3.37$3.605$3.35$3.491.21M
Sep 11, 2026$3.44$3.44$3.37$3.40356.23K
Sep 10, 2026$3.36$3.45$3.32$3.40480.12K
Sep 9, 2026$3.48$3.52$3.34$3.37520.71K
Sep 8, 2026$3.50$3.54$3.42$3.47705.97K
Sep 4, 2026$3.43$3.50$3.39$3.49487.72K
Sep 3, 2026$3.48$3.50$3.425$3.43237.36K
Sep 2, 2026$3.46$3.50$3.38$3.46418.34K
Sep 1, 2026$3.45$3.51$3.42$3.44392.76K
Aug 31, 2026$3.52$3.545$3.43$3.48427.01K
Aug 28, 2026$3.63$3.68$3.50$3.55695.6K
Aug 27, 2026$3.51$3.62$3.4699$3.62584.04K
Aug 26, 2026$3.62$3.62$3.38$3.461.01M
Aug 25, 2026$3.49$3.69$3.425$3.67895.95K
Aug 24, 2026$3.52$3.61$3.44$3.45898.34K
Aug 21, 2026$3.52$3.60$3.44$3.56615.3K
Aug 20, 2026$3.36$3.55$3.33$3.51811.74K
Aug 19, 2026$3.53$3.64$3.315$3.33713.63K
Aug 18, 2026$3.39$3.47$3.28$3.44905.07K

Latest NRXP news

The latest Smart Investors Daily articles mentioning NRXP.

Stock researchCompany · Overview

NRXP research

Overview

Company profile and research snapshot.

Company profile

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.00
Implied upside
—
Analysts
—
NRXP recent ratings
DateFirmRatingTarget
Sep 14, 2026BTIGBuy—
Aug 25, 2026HC Wainwright & Co.Buy—
Aug 18, 2026BTIGBuy—
Aug 7, 2026BTIGBuy—
May 5, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

WILMINGTON, Del., Sept. 08, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the management team will participate in three upcoming investor conferences in September 2026. Moody Capital Solutions 2026 Disruptive Growth & Life Sciences ConferenceCompany PresentationPresenter: Jonathan Javitt, M.D., M.P.H., Founder, Chairman and Chief Executive Officer of NRx PharmaceuticalsL

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By